Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Chemotherapy-Induced Peripheral Neuropathy Treatment Market Set to Expand, Forecasts DataM Intelligence

The global Chemotherapy-Induced Peripheral Neuropathy Treatment Market, valued at USD million in 2021, is poised for significant growth, according to a recent study by DataM Intelligence. Forecasted to reach USD million by 2031, the market is expected to grow at a CAGR of 5% during the forecast period spanning from 2024 to 2031.

Chemotherapy-induced peripheral neuropathy (CIPN) remains a critical clinical challenge induced by various chemotherapeutic drugs such as platinum, taxanes, and vinca alkaloids. These drugs inflict a range of pathological issues on neurons, leading to sensory disturbances, balance problems, and weakness in patients. The advancements in cancer treatment and diagnosis technologies coupled with the escalating incidence of CIPN are anticipated to fuel market expansion. Furthermore, the rising demand for cost-effective therapeutics in emerging regions presents lucrative opportunities for market growth.

DataM Intelligence's comprehensive analysis offers insights into the global market dynamics, encompassing quantitative and qualitative data. The report provides a detailed outlook and forecast for the global market, segmented by product, application, end-users, and region, extending until 2029. Major countries covered include the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and other global regions.

North America is expected to dominate the global market throughout the forecast period, with the United States and Canada contributing significantly. Meanwhile, Europe is projected to maintain a substantial presence globally from 2024 to 2031.

To know more Insights Download Sample: https://www.datamintelligence.com/download-sample/chemotherapy-induced-peripheral-neuropathy-treatment-market

Chemotherapy-Induced Peripheral Neuropathy Treatment Market Dynamics

Continuous research and development efforts are expected to underpin market growth during the forecast period. Key market players are investing in oncological research to develop efficient drugs and medications for managing CIPN. For instance, Paxman KTP introduced a novel device in December 2021 to prevent CIPN side effects. Collaboration with research institutes, such as Harvard Health Reviews, is also driving market expansion. However, adverse treatment effects pose a challenge to market growth.

Market Segmentation Analysis

The antidepressants segment holds the highest share in the global chemotherapy-induced peripheral neuropathy treatment market, offering clinically meaningful effects on CIPN. Platinum agents constitute a significant segment, with cisplatin being the most neurotoxic among them.

Geographical Share

North America dominates the global market, with the United States leading in contribution. The Asia-Pacific region is anticipated to witness substantial growth, attributed to developing healthcare infrastructure and rising awareness programs.

Companies and Competitive Landscape

The market is highly competitive, with key players including Regency Pharmaceuticals, Nemus Bioscience Inc., PledPharma, Immune PharmaceIncnc., and DermaXon LLC. These players are adopting new product launches and expansion strategies to enhance their global presence.

In March 2022, Asahi Kasei Pharma initiated a drug administration study for chemotherapy-induced peripheral neuropathy prevention. Novaremed's acquisition of Metys Pharmaceuticals in September 2021 aims to broaden its pipeline of non-opioid treatment candidates for chronic pain indications.

Related Reports:

Dravet syndrome therapeutics market: https://datamintelligence.com/research-report/dravet-syndrome-therapeutics-market
dermal-fillers-market: https://datamintelligence.com/research-report/dermal-fillers-market
facial injections market : https://datamintelligence.com/research-report/facial-injections-market
melanoma-therapeutics-market : https://datamintelligence.com/research-report/melanoma-therapeutics-market
non-opioid pain treatment market : https://datamintelligence.com/research-report/non-opioid-pain-treatment-market
peptide therapeutics market : https://datamintelligence.com/research-report/peptide-therapeutics-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.